FDA Jet Injector Policy To Be Addressed At Aug. 9 Advisory Panel
This article was originally published in The Gray Sheet
Executive Summary
FDA's General Hospital & Personal Use Devices Advisory Panel will convene Aug. 9 in Gaithersburg, Md. to discuss ways to evaluate cross-contamination risk for multiple-use nozzle jet injectors
You may also be interested in...
CDRH Keeps An Eye On Needle-Free Injector Policy Development
CDRH's General Hospital Devices Branch is highlighting needle-free injector devices as a technology focus in the near term
Bioject Dissatisfied With Panel Discussion On Jet Injector Guidance
Bioject Medical Technologies will be looking for more concrete guidance from FDA than was delivered by the agency's General Hospital and Personal Use Devices Advisory Panel, prior to pursuing approval for specific applications for the Biojector jet injector, the firm says.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.